Home › Research › Long-term cohort studies
Disease progression model for Clinical Dementia Rating-Sum of Boxes in mild cognitive impairment and Alzheimer's subjects from the Alzheimer's Disease Neuroimaging Initiative
Samtani MN, Raghavan N, Novak G, Nandy P, Narayan VA.. Neuropsychiatric disease and treatment, 2014-05-24
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background The objective of this analysis was to develop a nonlinear disease progression model, using an expanded set of covariates that captures the longitudinal Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) scores. These were derived from the Alzheimer's Disease Neuroimaging Initiative ADNI-1 study, of 301 Alzheimer's disease and mild cognitive impairment patients who were followed for 2-3 years. Methods The model describes progression rate and baseline disease score as a function of covariates.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study. This analysis developed a nonlinear disease progression model for Clinical Dementia Rating-Sum of Boxes scores using 301 Alzheimer's and mild cognitive impairment patients from ADNI-1 followed for 2-3 years. It is a modeling study of disease progression and does not test any treatment, cure, or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Samtani, M. N., Raghavan, N., Novak, G., Nandy, P., & Narayan, V. A. (2014). Disease progression model for Clinical Dementia Rating-Sum of Boxes in mild cognitive impairment and Alzheimer's subjects from the Alzheimer's Disease Neuroimaging Initiative. Neuropsychiatric disease and treatment. https://doi.org/10.2147/ndt.s62323
Vancouver
Samtani MN, Raghavan N, Novak G, Nandy P, Narayan VA. Disease progression model for Clinical Dementia Rating-Sum of Boxes in mild cognitive impairment and Alzheimer's subjects from the Alzheimer's Disease Neuroimaging Initiative. Neuropsychiatric disease and treatment. 2014. doi:10.2147/ndt.s62323. PMID: 24926196.
BibTeX
@article{samtani2014-24926196,
author = {Samtani, M. N. and Raghavan, N. and Novak, G. and Nandy, P. and Narayan, V. A.},
title = {{Disease progression model for Clinical Dementia Rating-Sum of Boxes in mild cognitive impairment and Alzheimer's subjects from the Alzheimer's Disease Neuroimaging Initiative}},
journal = {Neuropsychiatric disease and treatment},
year = {2014},
doi = {10.2147/ndt.s62323},
pmid = {24926196},
url = {https://doi.org/10.2147/ndt.s62323}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- These were derived from the Alzheimer's Disease Neuroimaging Initiative ADNI-1 study, of 301 Alzheimer's disease and mild cognitive impairment patients who were followed for 2-3 years.
- Methods The model describes progression rate and baseline disease score as a function of covariates.
- The covariates that were tested fell into five groups: a) hippocampal volume; b) serum and cerebrospinal fluid (CSF) biomarkers; c) demographics and apolipoprotein Epsilon 4 (ApoE4) allele status; d) baseline cognitive tests; and e) disease state and comedications.
- Results Covariates associated with baseline disease severity were disease state, hippocampal volume, and comedication use.
Why it matters
This analysis developed a nonlinear disease progression model for Clinical Dementia Rating-Sum of Boxes scores using 301 Alzheimer's and mild cognitive impairment patients from ADNI-1 followed for 2-3 years. It is a modeling study of disease progression and does not test any treatment, cure, or prevention.
Study details
- Study designlongitudinal study
- Evidence strengthModerate
How this study scored 47/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neuropsychiatric disease and treatment) |
| Journal's citation record | 1 / 4 | Neuropsychiatric Disease and Treatment: journal h-index 126 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2014 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 65 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 4.6 citations a year over 14 year(s) since 2014 |
| Impact for its field and year | 2 / 6 | Cited 2.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 5 other studies in this library |
| Still being cited | 2 / 4 | Cited 20 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Vaibhav A. Narayan: h-index 35 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Janssen Research & Development (United States): institution h-index 416 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 24926196) |
| Free to read | 2 / 2 | Free to read |
| Total | 47 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.2147/ndt.s62323
- PubMed: 24926196
- Original source →
- Free full text: Neuropsychiatric Disease and Treatment →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
5 studies in the alzhub library list this one in their references.
Related studies in Long-term cohort studies from nearby years
Also tagged “machine”
834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.